证券代码：600129 证券简称：太极集团 公告编号：2026-006 重庆太极实业（集团）股份有限公司 关于受让下属子公司股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： ●重庆太极实业（集团）股份有限公司（以下简称"公司"或"太 极集团"）拟分别受让重庆中药材有限公司（以下简称：重庆中药材 公司）持有重庆桐君阁中药批发有限责任公司（以下简称：桐君阁中 药批发）90%的股权以及太极集团重庆涪陵医药有限公司（以下简称： 涪陵医药）持有桐君阁中药批发10%股权。 ●本次股权转让均为公司与控股子公司之间进行，不涉及外部股 东，不会导致公司合并报表范围发生变化，不会对公司财务及经营状 况产生不利影响。 ●本次桐君阁中药批发股权转让事宜已经公司第十届董事会第 三十六次会议审议通过。根据《公司章程》规定，该事项无需提交公 司股东会审议。 ●本次股权转让事宜不构成《上海证券交易所股票上市规则》和 《公司章程》规定的关联交易，也不构成《上市公司重大资产重组管 理办法》规定的重大资产重组情形。 一、本次股权转让事宜 ...

证券代码：600129 证券简称：太极集团 公告编号：2026-008 重庆太极实业（集团）股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 召开地点：重庆市两江新区恒山东路 18 号公司 1201 会议室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 2 月 27 日 至2026 年 2 月 27 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东会召开当日的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者 的投票，应按照《上海证券交易所上市公司自律监管指引第 1 号 — 规范运 作》等有关规 ...

证券代码：600129 证券简称：太极集团 公告编号：2026-005 重庆太极实业（集团）股份有限公司 第十届董事会第三十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重庆太极实业（集团）股份有限公司（以下简称：公司）第十届 董事会第三十六次会议于 2026 年 2 月 4 日以邮件方式发出书面通知， 于 2026 年 2 月 6 日以现场及视频方式召开。本次会议由董事长俞敏 先生主持，会议应到董事 13 人，实到董事 13 人，公司部分高级管理 人员列席了会议。本次会议的召集、召开程序符合《公司法》和《公 司章程》的有关规定，会议合法有效。会议审议并通过了如下议案： 一、关于受让重庆桐君阁中药批发有限责任公司 100%股权的议 案（具体内容详见公司披露的《太极集团关于受让下属子公司股权的 公告》；公告编号：2026-006） 公司拟以现金 2,108 万元的价格受让全资子公司重庆中药材有 限公司持有重庆桐君阁中药批发有限责任公司 90%的股权；公司拟以 现金 235 万元的价格受让间接控股子公司太极集 ...

Core Viewpoint - The company intends to acquire a total of 90% and 10% stakes in Chongqing Tongjun Pavilion Traditional Chinese Medicine Wholesale Co., Ltd. for cash amounts of 21.08 million yuan and 2.35 million yuan, respectively, from its subsidiaries, which will not affect the financial and operational status of the company [1] Group 1 - The company will acquire 90% of the shares from Chongqing Chinese Medicinal Materials Co., Ltd. for 21.08 million yuan [1] - The company will also acquire 10% of the shares from Taiji Group Chongqing Fuling Pharmaceutical Co., Ltd. for 2.35 million yuan [1] - The share transfers are internal transactions between the company and its subsidiaries, not involving external shareholders [1] Group 2 - The transactions will not lead to changes in the company's consolidated financial statements [1] - There will be no adverse impact on the company's financial and operational conditions as a result of these acquisitions [1]

Core Viewpoint - The Chinese medicine industry is currently facing significant challenges, including regulatory changes that may lead to the elimination of many traditional Chinese medicine products, but this could also serve as an opportunity for industry upgrade and quality improvement [7][9][33]. Group 1: Industry Performance and Market Sentiment - After the "924" market trend in 2024, the Shenwan Chinese Medicine Index has been adjusted and has continued to consolidate, with a cumulative decline of over 10% [3]. - Even with performance forecasts indicating profit growth for Chinese medicine companies, the market has not responded positively, as seen with WoHua Pharmaceutical's net profit doubling yet experiencing a 6.01% drop in stock price the following day [4]. - The recent negative sentiment in the market is largely due to the impending withdrawal of a large number of traditional Chinese medicine products, as new regulations require clearer safety information on product labels [7][8]. Group 2: Regulatory Changes and Industry Impact - The new regulations state that any traditional Chinese medicine product with unclear safety information will not be approved for re-registration after July 1, 2026, affecting approximately 57,000 existing products, with over 70% facing safety information issues [7]. - The industry is experiencing a "compliance storm," which is seen not merely as a phase of elimination but as a catalyst for quality improvement and modernization of traditional Chinese medicine [9][11][33]. Group 3: Strategies for Development - To survive, companies must focus on supplementing safety data and revising product labels to ensure compliance with new regulations [15][16]. - Many leading companies have already completed the revision of their core products' labels, indicating a proactive approach to compliance [19]. - The compliance costs associated with these changes are manageable for companies with market support, as evidenced by several firms maintaining profitability despite the regulatory pressures [22][24]. Group 4: Innovation and Future Growth - Beyond compliance, companies need to invest in innovative research and development to ensure long-term growth, especially in a challenging market environment characterized by price reductions and weak consumer demand [27]. - New drug classifications in traditional Chinese medicine include ancient classic formulas, improved formulations, and innovative drugs, with the latter representing the highest potential for future competitiveness [28][30]. - Companies like Kangyuan Pharmaceutical and Shenwei Pharmaceutical are leading in innovation, having received multiple approvals for new products, indicating a focus on future growth opportunities [30][31].

Market Overview - The Chinese medicine sector experienced a decline of 0.98% on February 2, with Jilin Aodong leading the drop [1] - The Shanghai Composite Index closed at 4015.75, down 2.48%, while the Shenzhen Component Index closed at 13824.35, down 2.69% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Weikang Pharmaceutical (300878) with a closing price of 27.93, up 6.68% [1] - Foci Pharmaceutical (002644) with a closing price of 9.21, up 4.66% [1] - Significant decliners included: - Jilin Aodong (000623) with a closing price of 18.88, down 7.63% [2] - Datang Pharmaceutical (920433) with a closing price of 5.86, down 3.46% [2] Trading Volume and Capital Flow - The Chinese medicine sector saw a net outflow of 235 million yuan from institutional investors, while retail investors contributed a net inflow of approximately 51.97 million yuan [2] - The trading volume for Jilin Aodong reached 504,800 shares, with a transaction value of 977 million yuan [2] Individual Stock Capital Flow - Key capital flows for selected stocks included: - Dong'e Ejiao (000423) with a net inflow of 129 million yuan from institutional investors, but a net outflow of 18.04 million yuan from retail investors [3] - Foci Pharmaceutical (002644) had a net inflow of 43.42 million yuan from institutional investors, with a net outflow of 15.68 million yuan from retail investors [3]

Core Viewpoint - Taiji Group expects a significant increase in net profit for 2025, projecting approximately 110 million yuan, which represents a year-on-year growth of about 313% compared to the previous year [1] Financial Performance - The company anticipates a net profit attributable to shareholders of approximately 110 million yuan for 2025, an increase of about 83.35 million yuan from the previous year [1] - This growth reflects a substantial year-on-year increase of approximately 313% [1] Operational Strategy - Despite facing challenges such as declining sales volume and revenue due to policy impacts and inventory digestion, the company is focusing on its core business [1] - Taiji Group is actively transforming its marketing model and enhancing operational efficiency while controlling costs [1] - The company has implemented strict shipping controls and is prioritizing terminal sales, resulting in a significant reduction in inventory and stable operational quality [1]

(资料图) 证券日报网讯 1月30日，太极集团发布2025年年度业绩预增公告称，公司预计2025年年度归属于上市公 司股东的净利润约为11，000万元，与上年同期（法定披露数据）相比，增加约8，335万元，同比增幅 约313%。 ...

证券日报网讯 1月30日，太极集团发布2025年年度业绩预增公告称，公司预计2025年年度归属于上市公 司股东的净利润约为11，000万元，与上年同期（法定披露数据）相比，增加约8，335万元，同比增幅 约313%。 （编辑 任世碧） ...

Core Viewpoint - Taiji Group (600129) expects a significant increase in net profit for 2025, projecting approximately 110 million yuan, which represents a year-on-year growth of about 313% [1] Group 1: Financial Performance - The company anticipates a net profit of around 110 million yuan for 2025, reflecting a substantial increase of approximately 313% compared to the previous year [1] - Despite the expected profit growth, the company reported a decline in sales volume and revenue for its main products due to various adverse factors, including policy changes and ongoing inventory digestion [1] Group 2: Strategic Initiatives - In response to the challenging environment, the company is focusing on its core business and is actively pursuing a transformation in its marketing model to enhance quality and efficiency [1] - The company is strengthening operational management by reducing costs and controlling expenses, which is part of its strategy to maintain stable operational quality [1] - Strict control over shipments is being implemented, with an emphasis on promoting end-user sales, leading to a significant reduction in inventory levels [1]